Tag: biosimilar vs generic
Biologic Patent Protection: When Biosimilars Can Enter the Market
Explore how biologic patent protection delays biosimilar entry. We break down the 12-year BPCIA exclusivity, the patent dance, and why US patients pay more than global counterparts.
Insulin Biosimilars: Key Considerations and Real-World Market Examples
Insulin biosimilars offer major cost savings and proven safety-but they're not generics. Learn how they work, where they're used, and why adoption varies globally. Real market data and patient experiences included.